Articles from Forlong Biotechnology

Forlong Biotechnology, a clinical-stage biotech company focused on developing transformative cytokine therapies for patients with severe unmet needs, today announced that its manufacturing partner, JOINN Biologics, has successfully completed production of the FL115 pivotal batch, which will support the company’s upcoming Phase III clinical trial in non-muscle invasive bladder cancer (NMIBC).

Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe unmet needs, today announced that Phase I clinical studies of FL115, an IL-15 superagonist, as monotherapy via intravenous infusion in patients with advanced solid tumors have been completed, with durable treatment effects observed in 2 patients with confirmed partial response (cPR) and 1 patient with stable disease (SD).

Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe unmet needs, today announced the successful completion of an RMB 120 million (approximately USD 17.5 million) Series Pre-B financing. This round is co-led by an undisclosed fund and Fudan Capital, along with Changshu Guofa Venture, Kunsheng Relay Fund and other investors. Proceeds from the financing will be used to advance FL115, an IL-15 superagonist, into the pivotal clinical stage, and FL116, a PD-1/IL-18 bispecific, into clinic.

Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe unmet needs, today announced a poster presentation at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held from May 29 to June 2, 2026, at the McCormick Place in Chicago, IL.

Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe unmet needs, today announced that its FL115 Program has successfully completed technical transfer of manufacturing process and analytical methods by its manufacturing partner JOINN Biologics INC, and will soon initiate production of GMP batches to support upcoming pivotal clinical trial in nonmuscle invasive bladder cancer (NMIBC).

Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe unmet needs, today announced that preclinical data from its IL-15 and IL-18 programs will be presented at the 2026 AACR Annual Meeting held April 17-22, 2026 in San Diego, California.

Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe unmet needs, today announced that its Phase Ib/II study of FL115 (IL-15 Superagonist) in combination with anti-PD-1 antibody for patients with advanced solid tumor has been activated at the first clinical study site, Sun Yat-sen University Cancer Center; separately, its IND for FL115 Subcutaneous Injection has been accepted by Chinese NMPA.

Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe unmet needs, today announced that the first patient has been treated in a Phase 2 clinical trial investigating FL115 in combination with Bacillus Calmette-Guérin (BCG). The study will assess the anti-tumor effect of the combination therapy, including Complete Response Rate and Duration for carcinoma in situ (CIS) NMIBC patients, and Disease Free Survival and Relapse Free Survival for papillary (Ta/T1) NMIBC patients.

Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe unmet needs, today announced that a late-breaking abstract featuring interim safety and efficacy data from a Phase 1 study evaluating the Company’s novel IL-15 superagonist, FL115, has been selected for poster presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2025) being held November 5-9, 2025, in National Harbour, Maryland.

Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe unmet needs, today announced that it has entered into a collaboration agreement with Shanghai Henlius Biotech, Inc., (2696.HK) (“Henlius”) to develop innovative cancer immunotherapy with an engineered cytokine.

Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe unmet needs, today announced that it has received the first milestone payment under its licensing and collaboration agreements with Shell BioTech and a third party.